Meropenem Dosing in Hemodialysis
For intermittent hemodialysis (IHD), administer 500 mg every 24 hours for most infections, or 1 gram every 24 hours for severe infections or those caused by Pseudomonas aeruginosa, with a supplemental dose of 500 mg (or 1 gram for severe infections) given after each dialysis session. 1
FDA-Approved Dosing for Intermittent Hemodialysis
The FDA label explicitly states there is "inadequate information regarding the use of meropenem for injection in patients on hemodialysis" 1. However, the label provides clear guidance for severe renal impairment (CrCl <10 mL/min): administer one-half the recommended dose every 24 hours 1. This translates to:
- For complicated skin/soft tissue infections: 250 mg every 24 hours (or 500 mg every 24 hours if P. aeruginosa)
- For intra-abdominal infections: 500 mg every 24 hours
Post-Dialysis Supplementation
Since approximately 50% of meropenem is removed by IHD 2, a post-dialysis supplemental dose is necessary. Research supports administering the full dose after each dialysis session to maintain therapeutic levels 2, 3.
Practical regimen for IHD patients:
- Give 500 mg (or 1 gram for severe infections) every 24 hours on non-dialysis days
- Administer an additional 500 mg (or 1 gram) immediately after each dialysis session
- Infuse over 15-30 minutes 1
Continuous Renal Replacement Therapy (CRRT) Dosing
For patients on CRRT, administer 500 mg every 6-8 hours as a 3-hour infusion to achieve optimal pharmacodynamic targets. 4, 5
CRRT-Specific Considerations
The most recent population pharmacokinetic study (2025) demonstrates that CRRT increases meropenem clearance by 2.1-fold compared to non-CRRT patients with renal impairment 4. Key factors affecting clearance include:
Evidence-based CRRT dosing:
- Standard regimen: 500 mg every 6 hours as 3-hour infusion 4
- Alternative: 1 gram every 8 hours for severe infections or MIC >2 mg/L 6
- Continuous infusion option: 1-3 grams/day by continuous infusion for definitive therapy targeting 100% fT>4×MIC 5
Prolonged Intermittent RRT (PIRRT)
For PIRRT (sessions lasting 4-10 hours), the most recent 2026 modeling study recommends 7:
Alternate-day PIRRT:
- 1000 mg loading dose, then 500 mg every 8 hours (most session durations)
- Exception: 10-hour HD requires 1000 mg every 12 hours
Daily PIRRT:
- HD: 750 mg every 8 hours (4-8 hour sessions) or 1000 mg every 8 hours (10-hour sessions)
- HF: Ranges from 500 mg every 8 hours (4-hour) to 750 mg every 8 hours (10-hour sessions)
Critical Pitfalls to Avoid
Underdosing in CRRT: The FDA label's lack of specific CRRT guidance has historically led to underdosing 2. CRRT patients require doses approaching those for normal renal function due to significant drug removal.
Missing post-HD doses: Failure to give supplemental doses after dialysis results in subtherapeutic levels for 12-24 hours 2.
Ignoring effluent rates: Higher CRRT effluent rates (>300 mL/min) may require dose escalation to 1 gram every 8 hours 6, 5.
Neurotoxicity risk: While rare at standard doses, meropenem trough levels >64 mg/L increase seizure risk 8. This is unlikely with recommended renal dosing but monitor in patients with CNS pathology.
Augmented renal clearance: Some critically ill patients on CRRT paradoxically have augmented clearance requiring higher doses (up to 6 grams/day) 6, though this applies to patients with CrCl >60 mL/min, not typical dialysis patients.